Last reviewed · How we verify
Atropine Sulfate 1% Oph Soln
Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation.
Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation. Used for Mydriasis and cycloplegia for refraction and diagnostic examination, Uveitis and iritis, Accommodative esotropia.
At a glance
| Generic name | Atropine Sulfate 1% Oph Soln |
|---|---|
| Also known as | 1% atropine eye drops |
| Sponsor | State University of New York College of Optometry |
| Drug class | Anticholinergic agent / Muscarinic antagonist |
| Target | Muscarinic acetylcholine receptors (M1, M3) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Atropine is an anticholinergic agent that competitively antagonizes muscarinic receptors on the iris sphincter muscle and ciliary muscle. This prevents parasympathetic-mediated pupil constriction and lens accommodation, resulting in mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation). In ophthalmology, these effects are used diagnostically and therapeutically.
Approved indications
- Mydriasis and cycloplegia for refraction and diagnostic examination
- Uveitis and iritis
- Accommodative esotropia
- Myopia control (off-label use in some regions)
Common side effects
- Blurred vision
- Photophobia
- Eye irritation or discomfort
- Systemic anticholinergic effects (rare with topical use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: